Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at

Trial Details

NCT ID

NCT03539822

Phase

PHASE1 / PHASE2

Sponsor

Anwaar Saeed

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

• Cabozantinib
• Durvalumab
• Tremelimumab

Locations (sample)

• Westwood, Kansas, United States|39.04056,-94.6169
• Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

• Age ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Histologically confirmed diagnosis of any of the following:
• Gastric or gastroesophageal junction adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →